Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

683 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Precision Medicine in Head and Neck Cancers: Genomic and Preclinical Approaches.
Miserocchi G, Spadazzi C, Calpona S, De Rosa F, Usai A, De Vita A, Liverani C, Cocchi C, Vanni S, Calabrese C, Bassi M, De Luca G, Meccariello G, Ibrahim T, Schiavone M, Mercatali L. Miserocchi G, et al. Among authors: de rosa f, de vita a, de luca g. J Pers Med. 2022 May 24;12(6):854. doi: 10.3390/jpm12060854. J Pers Med. 2022. PMID: 35743639 Free PMC article. Review.
Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-α in patients with metastatic melanoma: a randomised "proof-of-principle" phase II study.
de Rosa F, Ridolfi L, Ridolfi R, Gentili G, Valmorri L, Nanni O, Petrini M, Fiammenghi L, Granato AM, Ancarani V, Pancisi E, Soldati V, Cassan S, Riccobon A, Parisi E, Romeo A, Turci L, Guidoboni M. de Rosa F, et al. J Transl Med. 2014 Jul 22;12:209. doi: 10.1186/1479-5876-12-209. J Transl Med. 2014. PMID: 25053129 Free PMC article. Clinical Trial.
Stability Program in Dendritic Cell Vaccines: A "Real-World" Experience in the Immuno-Gene Therapy Factory of Romagna Cancer Center.
Pancisi E, Granato AM, Scarpi E, Ridolfi L, Carloni S, Moretti C, Guidoboni M, De Rosa F, Pignatta S, Piccinini C, Soldati V, Calabrò L, Framarini M, Stefanelli M, Bulgarelli J, Tazzari M, Fanini F, Petrini M. Pancisi E, et al. Among authors: de rosa f. Vaccines (Basel). 2022 Jun 23;10(7):999. doi: 10.3390/vaccines10070999. Vaccines (Basel). 2022. PMID: 35891165 Free PMC article.
Complementary vaccination protocol with dendritic cells pulsed with autologous tumour lysate in patients with resected stage III or IV melanoma: protocol for a phase II randomised trial (ACDC Adjuvant Trial).
Ridolfi L, de Rosa F, Fiammenghi L, Petrini M, Granato AM, Ancarani V, Pancisi E, Soldati V, Cassan S, Bulgarelli J, Riccobon A, Gentili G, Nanni O, Framarini M, Tauceri F, Guidoboni M. Ridolfi L, et al. Among authors: de rosa f. BMJ Open. 2018 Aug 5;8(8):e021701. doi: 10.1136/bmjopen-2018-021701. BMJ Open. 2018. PMID: 30082356 Free PMC article.
Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients.
Ridolfi L, Petrini M, Granato AM, Gentilcore G, Simeone E, Ascierto PA, Pancisi E, Ancarani V, Fiammenghi L, Guidoboni M, de Rosa F, Valmorri L, Scarpi E, Nicoletti SV, Baravelli S, Riccobon A, Ridolfi R. Ridolfi L, et al. Among authors: de rosa f. J Transl Med. 2013 May 31;11:135. doi: 10.1186/1479-5876-11-135. J Transl Med. 2013. PMID: 23725550 Free PMC article.
Radiotherapy and High-Dose Interleukin-2: Clinical and Immunological Results of a Proof of Principle Study in Metastatic Melanoma and Renal Cell Carcinoma.
Bulgarelli J, Piccinini C, Petracci E, Pancisi E, Granato AM, de Rosa F, Guidoboni M, Petrini M, Ancarani V, Foschi G, Romeo A, Tontini L, De Giorgi U, Lolli C, Gentili G, Valmorri L, Rossi A, Ferroni F, Casadei C, Cortesi P, Crudi L, Ridolfi L. Bulgarelli J, et al. Among authors: de rosa f, de giorgi u. Front Immunol. 2021 Oct 27;12:778459. doi: 10.3389/fimmu.2021.778459. eCollection 2021. Front Immunol. 2021. PMID: 34777395 Free PMC article. Clinical Trial.
Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response.
Ridolfi L, de Rosa F, Ridolfi R, Gentili G, Valmorri L, Scarpi E, Parisi E, Romeo A, Guidoboni M. Ridolfi L, et al. Among authors: de rosa f. J Transl Med. 2014 Sep 23;12:262. doi: 10.1186/s12967-014-0262-6. J Transl Med. 2014. PMID: 25245327 Free PMC article. Clinical Trial.
683 results